DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022. About Precision BioSciences, Inc. Precision BioSciences, Inc. … [Read more…]
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. Enanta management will host … [Read more…]
Omnipod 5 is Now Fully Available through Retail Pharmacy Channels ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Omnipod® 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels … [Read more…]
DESHLER, Ohio–(BUSINESS WIRE)–#flowerpollenextract–Graminex®, L.L.C. is pleased to announce it has completed a clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health with positive results. This study was conducted as a randomized, double-blind, placebo-controlled, study to investigate the effectiveness of Graminex® Flower Pollen Extracts in 190 healthy women with urinary incontinence. … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Selective estrogen receptor degraders – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This “Selective Estrogen Receptor Degraders – Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and … [Read more…]
FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology®. The research article entitled Phase 1/2 Trial Results of a Large Surface Area Microparticle … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Medical Imaging Informatics Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Type, Application, and Components” report has been added to ResearchAndMarkets.com’s offering. The global medical imaging informatics market is expected to grow from US$ 3,671.72 million in 2021 to US$ 5,175.39 million by 2028; it is estimated to grow … [Read more…]
– State-of-the-art laboratory space will become available in 2025 – New building will bring SmartLabs to its third city in the United States BOSTON–(BUSINESS WIRE)–Capitalizing on Philadelphia’s emergence as a national hub for cell and gene therapy, SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, today announced plans to open its first facility in the city in … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Hospital-Acquired Disease Testing Market Analysis by Test Type (Pneumonia Stents, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Methicillin-Resistant Staphylococcus Aureus), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global hospital-acquired disease testing market size is estimated to be USD 1,500.4 million in 2021 and … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease” report has been added to ResearchAndMarkets.com’s offering. The global TNF Alpha Inhibitors market is expected to grow from $38.56 billion in 2021 to $40.73 billion in 2022 at a compound annual growth rate (CAGR) of 5.6%. The market is expected … [Read more…]
